Marshall Wace North America’s PDL BioPharma, Inc. PDLI Stock Holding History

Marshall Wace North America’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,311	Closed	-$40K	–	1771
2019 Q4	$40K	Buy	+12,311	New	+$35.7K	﹤0.01%	1172
2018 Q2	–	Sell	-11,819	Closed	-$35K	–	1932
2018 Q1	$35K	Buy	+11,819	New	+$32.3K	﹤0.01%	1389
2017 Q4	–	Sell	-88,446	Closed	-$265K	–	1811
2017 Q3	$265K	Buy	+88,446	New	+$246K	﹤0.01%	1148

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marshall Wace North America's PDLI Position: Q1 2020 in Review

Marshall Wace North America sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 12,311 shares — an estimated $40K sold.

Marshall Wace North America first reported a position in PDLI in Q3 2017 and held it in 3 quarters. The position peaked at $265K in Q3 2017. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

Marshall Wace North America reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
Marshall Wace North America sold 12,311 PDL BioPharma, Inc. shares in Q1 2020, an estimated $40K.
Marshall Wace North America first reported a position in PDL BioPharma, Inc. in Q3 2017 and held it in 3 quarters.
Marshall Wace North America's PDL BioPharma, Inc. position peaked at $265K in Q3 2017.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.